Established in Edinburgh, UK, in 2006, Roslin Cells has spent the last decade developing into a leader in the “development, optimization, scale up and the GMP manufacture of Cell Therapy and Advanced Therapy Medicinal Products (ATMPs).” With major facilities in both Edinburgh and Cambridge, the company can produce large volumes of cell lines from different donors, allowing pharmaceutical researchers to assess how drug performance can differ from individual to individual.
On January 11th, 2016, Roslin Cells announced major news that it is creating two subsidiary companies, one to facilitate “process development and manufacture of cell therapies for clinical trials” and the other to “focus on the production and use of human induced Pluripotent Stem Cells (iPSCs) for drug discovery.” This will strengthen Roslin Cell’s position as a leader in both clinical-grade cell manufacturing and in iPSC production for drug discovery applications. [Read more…]